Pediatric Use Alternatives Should Not Be Required In Labeling - PhRMA
This article was originally published in The Tan Sheet
Executive Summary
FDA's requirement for labeling to recommend preferential use of competitor products that have positive pediatric data would make it appear the subject drug has been found inferior in comparative trials, the Pharmaceutical Research & Manufacturers of America maintains in comments on FDA's pediatric rule draft guidance.